BioCentury
ARTICLE | Strategy

Against the wind

How Biogen plans to restore Tecfidera sales and find its future growth arc

October 26, 2015 7:00 AM UTC

An unexpected slowing of Biogen Inc.'s key growth engine and two clinical setbacks in multiple sclerosis have led management to reallocate resources toward marketing support for Tecfidera dimethyl fumarate and simultaneous development of multiple late-stage assets.

The challenge for the company is to recharge sales momentum for Tecfidera - against headwinds in the U.S. MS category - to sustain top-line growth until new products can reach the market...